Does Rallies show DRUG 10-K and 10-Q filings?

Rallies organizes DRUG SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.

Is DRUG research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DRUG. It does not provide personalized investment advice.

DRUG (Bright Minds Biosciences Inc. Common Stock) Stock Analysis - SEC Filings

Bright Minds Biosciences Inc. Common Stock (DRUG) is a publicly traded Healthcare sector company. As of May 21, 2026, DRUG trades at $83.00 with a market cap of $734.04M and a P/E ratio of 0.00. DRUG moved +11.07% today. Year to date, DRUG is +3.46%; over the trailing twelve months it is +155.02%. Its 52-week range spans $0.94 to $123.75. Analyst consensus is strong buy with an average price target of $145.67. Rallies surfaces DRUG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find DRUG SEC filings?

Rallies organizes DRUG SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

DRUG Key Metrics

Key financial metrics for DRUG
Metric	Value
Price	$83.00
Market Cap	$734.04M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$123.75
52-Week Low	$0.94
Volume	41
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Latest DRUG News

Helus HLP004 Phase 2 Posts 10.4-Point HAM-A Gain; BPL-003 Phase 3 Wins FDA Nod — Mar 6, 2026
Bright Minds Price Target Falls to $126, BMB-101 Cuts Seizures Over 60% — Feb 19, 2026
Canadian Securities Exchange Records 2.0 Billion Shares and $446 Million Financing in January — Feb 17, 2026
Bright Minds Biosciences Raises $175M via 1.945M Share Offering at $90 — Jan 9, 2026
Bright Minds Biosciences’ BMB-101 Cuts Absence Seizures by 73% and Boosts REM Sleep 90% — Jan 8, 2026

Recent DRUG Insider Trades

Cormorant Asset Management, LP sold 109.33K (~$9.79M) on Apr 28, 2026.
Cormorant Asset Management, LP bought 184.33K (~$4.00M) on Nov 4, 2024.
Cormorant Asset Management, LP bought 39.74K (~$922.63K) on Oct 16, 2024.

DRUG Analyst Consensus

3 analysts cover DRUG: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $145.67.

Common questions about DRUG

Where can I find DRUG SEC filings?: Rallies organizes DRUG SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show DRUG 10-K and 10-Q filings?: Rallies organizes DRUG SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is DRUG research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DRUG. It does not provide personalized investment advice.